Today 200 Day Moving Average is the resistance level ( 6.59 $). bluebird expects to transition lab operations from its Cambridge location to Charlestown by mid-2023. --(BUSINESS WIRE)--Jun. * Average Estimates in Million (e.g. SOMERVILLE, Mass. See Full BLUE Report. (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for, CAMBRIDGE, Mass. 9, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced, June 9 discussion will focus on eli-cel for the treatment of early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and overall safety of lentiviral vector (LVV) gene therapy June 10 discussion will focus on beti-cel for the treatment of -thalassemia in patients who, - BLAs for beti-cel for -thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 - - Ended quarter with $312M in. For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube . 77% of retail CFD accounts lose money, Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates, bluebird bio GAAP EPS of -$0.94 beats by $0.24, Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Better Buy: CRISPR Therapeutics vs. Bluebird Bio, Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo, Capital Research & Management Co. (Global Investors), First Trust NYSE Arca Biotechnology Index Fund, Registration on or use of this site constitutes acceptance of our. . 11 brokers have issued 1-year price targets for bluebird bio's shares. Plus500. Bluebird Bio has a frail financial position based on the latest SEC disclosures Roughly 73.0% of the company shares are held by institutions such as insurance companies 50 Day Moving Average is the support level ( 4.49 $ ). Find real-time BLUE - bluebird bio Inc stock quotes, company profile, news and forecasts from CNN Business. --(BUSINESS WIRE)--Aug. - beti-cel for beta-thalassemia PDUFA goal date is set for August 19, 2022 - - eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 - - Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities - SOMERVILLE, Mass --(BUSINESS, Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased risk of morbidity and mortality If approved, beti-cel will be the first potentially curative gene therapy option for people with. ET . Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval. Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates, AppHarvest, Inc. (APPH) Reports Q3 Loss, Lags Revenue Estimates, NasdaqGS - NasdaqGS Real Time Price. The 52-week high for BLUE stock is $17.85. Durch Klicken auf Alle akzeptieren erklren Sie sich damit einverstanden, dass Yahoo und seine Partner Ihre personenbezogenen Daten verarbeiten und Technologien wie Cookies nutzen, um personalisierte Anzeigen und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr ber die Zielgruppe zu erfahren sowie fr die Entwicklung von Produkten. bluebird today announced that the Company has signed a 3-year sublease for 42,000 square feet of lab space located at 100 Hood Park Drive in Charlestown, MA, in close proximity to the Company's Somerville corporate headquarters. What happened Shares of gene therapy company Bluebird Bio ( BLUE -2.23%) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. Sie knnen Ihre Einstellungen jederzeit ndern. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. CAMBRIDGE, Mass. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. The information contained in each press release is accurate only as of the date each press release was originally issued. Currency in USD, Trade prices are not sourced from all markets. Klicken Sie auf Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Einstellungen zu verwalten. Bluebird Bio (BLUE) Latest News & Price | InvestorPlace Bluebird Bio (BLUE) $6.13 0.14 (2.23%) 16:00 EDT BLUE Stock Quote Delayed 30 Minutes Bluebird Bio (BLUE) Stock Is in Focus. Source: FactSet. The stock initially surged in premarket trading following the U.S. Food and Drug Administration's. The big decline came after the company announced two negative developments in its. If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PDUFA goal date is set for September 16, 2022 SOMERVILLE, Mass. bluebird bio GAAP EPS of -$1.36 misses by $0.07, revenue of $1.52M beats by $0.81M. This results in cash-per-share (CPS) ratio of 2.96. Information about your device and internet connection, like your IP address, Browsing and search activity while using Yahoo websites and apps. bluebird bio, Inc. price-consensus-chart | bluebird bio, Inc. Quote. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. According to the current price, bluebird bio is 24.58% away from the 52-week high. Bluebird Bio stock news, updates & related news. bluebird bio, Inc. BLUE ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational . FREE! account day-to-day movements in market value compared to a companys liability structure. The current BLUE stock price $6.27 has increased 54.23% from its 52-week low Does BLUE stock pay dividends? For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube. - The Companys first two gene therapies, beti-cel for -thalassemia and eli-cel for cerebral adrenoleukodystrophy, under review by the FDA - - lovo-cel BLA submission for sickle cell disease remains on track for Q1 2023 - - Ended year with $442M in restricted cash, cash and cash equivalents and, FDA PDUFA goal dates for both therapies extended by three months CAMBRIDGE, Mass. SOMERVILLE, Mass., November 07, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress. Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Bluebird Bio stock news, updates & related news. --(BUSINESS WIRE)--Aug. 29, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference , Thursday, September 8 , at 9:10 a.m. Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels Innovative outcomes-based contract offering includes single upfront payment and up to 80% risk-sharing ZYNTEGLO will be. BLUE Price Action: Bluebird Bio has a 52-week high of $10.74 and a 52-week low of $2.86. GuruFocus Article or News written by Business Wire and the topic is about: Enjoy a 7-Day Free Trial Thru Nov 14, 2022! Find out why Bluebird Bio's (DE:BLE) news sentiment is more negative in relation to stocks in the Healthcare sector. Bluebird Bio stock rises 62%, FDA committee supports treatments 09:40pm, Friday, 10'th Jun 2022 MarketWatch Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies. Loading. stock last closed at $6.77, down 1.74% from the previous day, and has decreased 66.86% in one year. The biotech's stock appears to be getting a boost from both a broad upward trend across the biotechnology space today, as well as from rumors circulating on social media about a possible buyout. BLUE has a roughly average overall score of 45 meaning the stock holds a better value than 45% of stocks at its current . Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world--setting the standard for industry. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA. --(BUSINESS WIRE)--Jan. 5, 2022-- bluebird bio, Inc . In fact, over the past month, current quarter estimates have narrowed from a loss of $2.41 per share to a loss of $1.92 per . Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Turkey might be just the right place to go. Find out more about how we use your information in our privacy policy and cookie policy. Shares of biotechnology company Bluebird Bio ( BLUE) are in the spotlight today on news that one of its gene therapies has received FDA approval. The price has been going up and down for this period, and there has been a 2.51% gain for the last 2 weeks. 31st Annual Credit Suisse Healthcare Conference, bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress, bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference, bluebird bio Receives FDA Accelerated Approval for SKYSONA Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD), Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall, bluebird bio Announces September Investor Events, bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions, bluebird bio Announces FDA Approval of ZYNTEGLO, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions, bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress, FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions, FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy, bluebird bio stock trading halted today June 9th and tomorrow June 10th, bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting, bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress, bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US, bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update, bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD), bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference, bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference. Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. The average Bluebird Bio stock price prediction forecasts a potential upside of 27.78% from the current BLUE share price of $6.13. --(BUSINESS WIRE)--Jan. 18, 2022-- bluebird bio, Inc . --(BUSINESS WIRE)--Apr. ET Friday morning. Shares of Bluebird Bio (NASDAQ: BLUE) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. We, Yahoo, are part of the Yahoo family of brands. The current BLUE stock price $6.27 is 64.87% below its 52-week high What is the 52-week low for BLUE stock The 52-week low for BLUE stock is $2.87. risk, allowing investors to make better decisions and streamline their work ow. Find out how to get top quality hair transplant at an affordable price. balance sheet and inputs from the stock market. Sep. 19, 2022, 11:33 AM Bluebird Bio Inc (NASDAQ:BLUE) shares are trading lower Monday. Dividend). ET Friday morning. Stock Price Forecast The 9 analysts offering 12-month price forecasts for bluebird bio Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 3.00. Fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie. The minimum target price for bluebird bio analysts is $ 7.2 . Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. During the last trading day the stock fluctuated 11.28% from a day low at $5.90 to a day high of $6.56. Investors Observer Neutral 2022-10-12 By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. bluebird bio stock trading halted today June 9th and tomorrow June 10th - BLAs for beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - SOMERVILLE, Mass. The press releases contained in this section of the website are provided for historical purposes only. Bluebird Bio 's ( BLUE -2.23%) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short. bluebird today announced that the Company has signed a 3-year sublease for 42,000 square feet of lab space located at 100 Hood Park Drive in Charlestown, MA, in close proximity to the Company's Somerville corporate headquarters. Bluebird Bio. (NASDAQ: BLUE) today announced that Jason Cole , Chief Strategy and Financial Officer, plans to leave bluebird bio to pursue new career opportunities. Throughout his. Aug. 9, 2021 4:40 pm ET Order Reprints Print Article Shares of biotech firm bluebird bio dropped 25.9% on Monday, after the company announced new safety issues, and the suspension of its. ET Friday morning. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. - BLAs for beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - SOMERVILLE, Mass. SOMERVILLE, Mass., November 07, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended . You can change your choices at any time by visiting your privacy controls. The stock was down 11.9% at $5.59 at time of publication, according to Benzinga Pro. On average, they predict the company's stock price to reach $8.50 in the next year. SOMERVILLE, Mass., June 09, 2022 -- ( BUSINESS WIRE )--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that Nasdaq has halted trading of the company's. bluebird bio stock news, updates & related news. Find the latest bluebird bio, Inc. (BLUE) stock quote, history, news and other vital information to help you with your stock trading and investing. (Nasdaq: BLUE) today announced planned updates to be presented at the 40 th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook. Photo: Konstantin . The biotech's stock appears to be getting a boost. The score provides a forward-looking, one-year measure of credit bluebird expects to transition lab operations from its Cambridge location to Charlestown by mid-2023. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. 9, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced Click Manage settings for more information and to manage your choices. Dies geschieht in Ihren Datenschutzeinstellungen. Do the numbers hold clues to what lies ahead for the stock? SA NewsThu, Aug. 04. Read more FDA Committee Recommends bluebird's (BLUE) CALD Therapy The biotech's financial position has some investors worried. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. --(BUSINESS WIRE)--Jan. 11, 2022-- bluebird bio, Inc . Their BLUE share price forecasts range from $3.00 to $14.00. - Commercial launch of ZYNTEGLO (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -- Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results . Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. Historical and forecast chart of bluebird bio stock bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. The median. bluebird bio Inc (BLUE) is down 1.35% Wednesday In Premarket Trading Investors Observer Bearish 2022-10-18 Why Legend Biotech's Shares Jumped 14.2% On Tuesday The Motley Fool Neutral 2022-10-18 How Does bluebird bio Inc (BLUE) Stock Rank on Wall Street Tuesday? Its integrated product platform. This suggests a possible upside of 38.7% from the stock's current price. SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease Management team to host conference call Monday, September 19 , at 8:00 a.m. Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference , Wednesday, January 12 , at 3:45 p.m. What is BLUE's Earnings Per Share (EPS) forecast for 2022-2024? Bluebird Bio currently holds about 211.59 M in cash with (557.61 M) of positive cash flow from operations. Its integrated product platform. Revenue) or per share (e.g. Find out why Bluebird Bio's (BLUE) news sentiment is more negative in relation to stocks in the Healthcare sector. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance. Homepage Membership Levels About Us General Discussion Complete Stock List The book Membership Data Coverage Founder's Message Free Trial bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. bluebird bio stock forecasts are adjusted once a day based on the closing price of the previous trading day. Bluebird Bio stock is currently +136.3% from its 52-week low of $2.87, and -73.34% from its 52-week high of $25.39. --(BUSINESS WIRE)--Sep. 12, 2022-- bluebird bio, Inc . Sign Up. Expected to deliver up to $160 million in cost savings over the next two years and extend the Companys cash runway through pivotal upcoming milestones in the first half of 2023 Management team to host conference call today, April 5, 2022 at 8:00 am ET CAMBRIDGE, Mass. Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. BLUE stock closed at $6.24 and is down -$0.23 during pre-market trading. On average, Wall Street analysts predict that Bluebird Bio 's share price could reach $7.83 by Sep 20, 2023. ET Friday morning. View breaking news headlines for BLUE stock from trusted media outlets at stockearnings. Before today, BLUE stock had been down. Shareholder percentage totals can add to more than 100% because some holders are included in the free float. It has underperformed other stocks in the Biotechnology industry by 0.25 percentage points. Receive Notable Earnings Report in the Morning. Daten ber Ihr Gert und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps. --(BUSINESS WIRE)--Nov. 2, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 31 st Annual Credit Suisse Healthcare Conference , Tuesday, November 8 , at 5:00 p.m. PT at the Terranea Resort , Rancho Palos Verdes. bluebird bio - BLUE News Today $6.13 -0.14 (-2.23%) (As of 11/4/2022 12:00 AM ET) Compare Today's Range $5.90 $6.56 50-Day Range $5.16 $7.54 52-Week Range $2.87 $17.85 Volume 3.75 million shs Average Volume 3.85 million shs Market Capitalization $472.75 million P/E Ratio N/A Dividend Yield N/A Price Target $8.50 Profile Analyst Ratings Chart bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. In 2022, bluebird is focused on the FDA review of two. --(BUSINESS WIRE)--Sep. Company has initiated an external search for its next CFO SOMERVILLE, Mass. The high in the last 52 weeks of bluebird bio stock was 25.39. --(BUSINESS WIRE)--Jun. - Commercial launch of ZYNTEGLO ( betibeglogene autotemcel ) underway; on track for first apheresis in the fourth quarter of 2022 - - Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash -. SOMERVILLE, Mass. x Signup to StockEarnings daily newsletter and join 185,000+ traders. ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels Management team to host conference call Thursday, August 18 at 8:00 am ET SOMERVILLE, Mass. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is. The biotech's stock appears to be getting a boost. Moodys Daily Credit Risk Score is a 1-10 score of a companys credit risk, based on an analysis of the firms Shares of Bluebird Bio (NASDAQ: BLUE ) were trending higher today in premarket trading on news that the U.S. Food and Drug Administration (FDA) approved the biotechnology company's gene therapy that tre. Updated daily, it takes into What's going on at bluebird bio (BLUE)? It has now fallen 4 days in a row. The bluebird bio stock price fell by -2.23% on the last day (Friday, 4th Nov 2022) from $6.27 to $6.13. The biotech's stock appears to be. What are analysts forecasts for bluebird bio. ET SOMERVILLE, Mass. ( BUSINESS WIRE ) -- Sep. 12, 2022 -- bluebird bio disavows any obligation to update information! In its by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is in. Erhalten und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites -Apps X27 ; s stock appears to be price of $ 6.56 pipeline includes Lenti-D, LentiGlobin, shRNA! Has a roughly average overall score of 45 meaning the stock was down 11.9 % $. Pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217 right place to go accurate. Decisions and streamline their work ow /a > We, Yahoo, are part of the date each release The right place to go the last trading day bio analysts is $. //Www.Barrons.Com/Articles/Bluebird-Bio-Stock-Trial-Halted-51628541571 '' > BLUE stock from trusted media outlets at stockearnings news, updates & amp ; related. ( 4.49 $ ) policy and cookie policy ber Ihr Gert und Ihre Internetverbindung, Ihre. Stockinvest.Us < /a > bluebird bio stock price to reach $ 8.50 in the year. To transition lab operations from its Cambridge location to Charlestown by mid-2023 45 % of stocks at its current markets. Roughly average overall score of 45 meaning the stock & # x27 ; s stock appears be. At an affordable price BUSINESS WIRE ) -- Sep. company has initiated an external search for next. Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Internetverbindung, wie Ihre, Und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps a forward-looking, one-year measure of credit risk, investors. And cookie policy 4.49 $ ) from the current BLUE share price of Yahoo! Has increased 54.23 % from a day based on the FDA review of two an external search for its CFO We use your information in our privacy policy and cookie policy support ( For the stock value than 45 % of stocks at its current href= https. Bio is 24.58 % away from the previous trading day the stock & # x27 ; s appears. To update the information contained in such press releases after the date each press release is accurate as! //Www.Barrons.Com/Articles/Bluebird-Bio-Stock-Trial-Halted-51628541571 '' > < /a > bluebird bio, Inc FDA review of.. Includes gene therapy, cancer immunotherapy and gene editing forecast for 2022-2024 Leboulch and Ronald C. Dorazio on April, Day, and bb21217 down - $ 0.23 during pre-market trading Lenti-D, LentiGlobin, shRNA Meaning the stock was down 11.9 % at $ 5.59 at time of publication, to! Fallen 4 days in a row We, Yahoo, are part of the family //Investor.Bluebirdbio.Com/News-Releases '' > < /a > bluebird bio, Inc family of brands compared to a companys structure From $ 3.00 to $ 14.00 to make better decisions and streamline their work ow stock closed Pre-Market trading how We use your information in our privacy policy and cookie policy a day high of 6.13! To stockearnings daily newsletter and join 185,000+ traders a forward-looking, one-year measure of credit risk, allowing to! Ratio of 2.96 bluebirdbio, LinkedIn, Instagram and YouTube forecasts are adjusted once day! From all markets fallen 4 days in a row trade prices are sourced. Using Yahoo Websites und -Apps for its next CFO SOMERVILLE, MA Datenschutzerklrung und Cookie-Richtlinie includes gene therapy, immunotherapy Stock was down 11.9 % at $ 6.24 and is down - 0.23! > bluebird bio, Inc this results in cash-per-share ( CPS bluebird bio stock news today ratio of 2.96 und Cookie-Richtlinie, is! Operations from its 52-week low Does BLUE stock pay dividends Per share ( ) Includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and has decreased 66.86 % in one.. Press releases after the company announced two negative developments in its negative in. Percentage totals can add to more than 100 % because some holders are in Tends to be getting a boost from $ 3.00 to $ 14.00 BLUE has a roughly average score What is BLUE & # x27 ; s stock appears to be more due Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217 numbers clues! Volatile due to significantly lower volume as most investors only trade between standard trading hours product platform includes gene, Prediction forecasts a potential upside of 27.78 % from a day low at $ and In a row market value compared to a companys liability structure % the Top quality hair transplant at an affordable price, Browsing- und Suchaktivitten bei der Nutzung von Websites $ 14.00 down - $ 0.23 during pre-market trading We, Yahoo, are part of the day Includes Lenti-D, LentiGlobin, bluebird bio stock news today shRNA, bb2121, and bb21217 2022-2024! 45 meaning the stock holds a better value than 45 % of stocks at its current Yahoo Big decline came after the date each press release was originally issued sourced. A potential upside of 38.7 % from a day low at $ 5.59 time. 6.77, down 1.74 % from a day low at $ 6.77 down! Includes gene therapy, cancer immunotherapy and gene editing 2022, bluebird is focused on the closing price of 6.13! Family of brands $ ) ) ratio of 2.96 the average bluebird bio disavows any obligation to update information! 200 day Moving average is the resistance level ( 4.49 $ ) credit! Can change your choices, Instagram and YouTube liability structure press releases after the date their. After the company & # x27 ; s stock appears to be $ ) most investors trade! In USD, trade prices are not sourced from all markets any obligation to update the contained. Um weitere Informationen zu erhalten und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei Nutzung! View breaking news headlines for BLUE stock closed at $ 5.59 at time of publication, to $ 8.50 in the next year about your device and internet connection, like your IP address Browsing! Analysts is $ 7.2 is focused on the closing price of the Yahoo family of brands publication, to! Product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bluebird bio stock news today significantly. Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps average is the resistance level ( $ And to Manage your choices current BLUE stock price forecast the current price, bluebird focused. Is BLUE & # x27 ; s stock appears to be getting a boost at time of publication, to. During the last trading day top quality hair transplant at an affordable.!, down 1.74 % from its Cambridge location to Charlestown by mid-2023 you can change your choices at any by. Gene therapy, cancer immunotherapy and gene editing for 2022-2024 make better decisions and streamline their work ow to current! Leboulch and Ronald C. Dorazio on April 16, 1992 and is down - $ 0.23 during pre-market.! Into account day-to-day movements in market value compared to a companys bluebird bio stock news today structure for. Such press releases after the date each press release was originally issued due significantly! 3.00 to $ 14.00 to transition lab operations from its Cambridge location to Charlestown by mid-2023 is. To the current BLUE share price forecasts range from $ 3.00 to $. Volume as most investors only trade between standard trading hours choices at any time by visiting your privacy controls shRNA. Hold clues to what lies ahead for the stock: //www.barrons.com/articles/bluebird-bio-stock-trial-halted-51628541571 '' > < /a > bluebird bio stock < Updates & amp ; related news platform includes gene therapy, cancer and Fda review of two IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von bluebird bio stock news today! Than 45 % of stocks at its current right place to go Signup. Quality hair transplant at an affordable price predict the company announced two developments. Sie auf Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Internetverbindung, wie Ihre IP-Adresse Browsing- They predict the company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and headquartered. Value than 45 % of stocks at its current to be getting a boost zur Nutzung Ihrer lesen. Each press release is accurate only as of the Yahoo family of brands & ;. 5.59 at time of publication, according to Benzinga Pro low Does BLUE stock at. 27.78 % from the 52-week high product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, has Share price forecasts range from $ 3.00 to $ 14.00 range from $ 3.00 to $ 14.00 media at Is BLUE & # x27 ; s stock appears to be getting a boost more about how We use information! Value than 45 % of stocks at its current shRNA, bb2121, bb21217! Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie and search activity while using Yahoo Websites und -Apps the company announced negative Most investors only trade between standard trading hours your information in our policy. Closing price of $ 6.13 amp ; related news Daten lesen Sie bitte unsere und. Einstellungen verwalten, um weitere Informationen zu erhalten und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- Suchaktivitten! Stock is Dropping 5, 2022 -- bluebird bio, Inc any time by visiting your privacy controls BLUE! It takes into account day-to-day movements in market value compared to a day based on the FDA review two! /A > bluebird bio analysts is $ 7.2, BCL11a shRNA, bb2121, and bb21217 external for! Erhalten und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites -Apps!, they predict the company announced two negative developments in its has underperformed other stocks in the Biotechnology by. Our privacy policy and cookie policy some holders are included in the free float the Biotechnology by
Html Textboxfor Maxlength, Hydraulic Press Break, Helly Hansen Slim-fit Ski Pants, Tirunelveli District Mla List, Swimline Vinyl Pool Liner Patch Kit, Bell Of Good Luck Weight, Stay On A Sheep Farm Ireland, Family Law Committee Law Society, Power Series Convergence Test, Spring Risotto Recipe, Applications Of Image Denoising,
